个人科研网厅 | | 帮助
首都医科大学宣武医院知识库
高级检索
当前位置： 首页 > 详情页

Strategies for the use of Ginkgo biloba extract, EGb 761®, in the treatment and management of mild cognitive impairment in Asia: Expert consensus (Open Access)

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ SSCI

作者：
Kandiah, N[1,2,3,*1] * ; Chan, Y.F[4] ; Chen, C[5] ; Dasig, D[6] ; Dominguez, J[7] ; Han, S.-H[8] ; Jia, J[9] ; Kim, S[10] ; Limpawattana, P[11] ; Ng, L.-L[12] ; Nguyen, D.T[13] ; Ong, P.A[14] ; Raya-Ampil, E[15] ; Saedon, N[16] ; Senanarong, V[17] ; Setiati, S[18] ; Singh, H[19] ; Suthisisang, C[20] ; Trang, T.M[21] ; Turana, Y[22] ; Venketasubramanian, N[23] ; Yong, F.M[24] ; Youn, Y.C[25] ; Ihl, R[26] ;
机构： [a]National Neuroscience Institute, Singapore, Singapore [b]Duke-NUS, Singapore, Singapore [c]Lee Kong Chian-Imperial College, Singapore, Singapore [d]Hospital Kuala Lumpur, Kuala Lumpur, Malaysia [e]Departments of Pharmacology and Psychological Medicine, Yong Loo Lin School of Medicine, Memory Aging and Cognition Centre, National University of Singapore, Singapore, Singapore [f]Makati Medical Center, Manila, Philippines [g]St Luke's Medical Center, Manila, Philippines [h]Konkuk University Medical Center, Seoul, South Korea [i]Xuanwu Hospital, Capital Medical University, Beijing, China [j]Department of Neurology, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seoul, South Korea [k]Srinakarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand [l]Changi General Hospital, Singapore, Singapore [m]Department of Internal Medicine, University of Medicine and Pharmacy, Hue University, Hue City, Viet Nam [n]Hasan Sadikin General Hospital, Jawa Barat, Indonesia [o]University of Santo Tomas, Metro Manila, Philippines [p]Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia [q]Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand [r]Department of Internal Medicine, Cipto Mangunkusumo Hospital, Jakarta, Indonesia [s]Dr Harjot Singh's Neuropsychiatry Centre and Hospital, Amritsar, India [t]Faculty of Pharmacy, Mahidol University, Bangkok, Thailand [u]Department of Neurology, University Medical Center, Ho Chi Minh City, Viet Nam [v]School of Medicine and Health Science, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia [w]Raffles Neuroscience Centre, Raffles Hospital, Singapore, Singapore [x]Subang Jaya Medical Centre, Selangor, Malaysia [y]Chung-Ang University Medical Center, Seoul, South Korea [z]Alexian Hospital, Krefeld, Germany
出处：
DOI： 10.1111/cns.13536
ISSN：

关键词： cerebrovascular disease dementia EGb 761® Ginkgo biloba mild cognitive impairment neuropsychiatric symptoms

摘要：
Background: Mild cognitive impairment (MCI) is a neurocognitive state between normal cognitive aging and dementia, with evidence of neuropsychological changes but insufficient functional decline to warrant a diagnosis of dementia. Individuals with MCI are at increased risk for progression to dementia; and an appreciable proportion display neuropsychiatric symptoms (NPS), also a known risk factor for dementia. Cerebrovascular disease (CVD) is thought to be an underdiagnosed contributor to MCI/dementia. The Ginkgo biloba extract, EGb 761®, is increasingly being used for the symptomatic treatment of cognitive disorders with/without CVD, due to its known neuroprotective effects and cerebrovascular benefits. Aims: To present consensus opinion from the ASian Clinical Expert group on Neurocognitive Disorders (ASCEND) regarding the role of EGb 761® in MCI. Materials & Methods: The ASCEND Group reconvened in September 2019 to present and critically assess the current evidence on the general management of MCI, including the efficacy and safety of EGb 761® as a treatment option. Results: EGb 761® has demonstrated symptomatic improvement in at least four randomized trials, in terms of cognitive performance, memory, recall and recognition, attention and concentration, anxiety, and NPS. There is also evidence that EGb 761® may help delay progression from MCI to dementia in some individuals. Discussion: EGb 761® is currently recommended in multiple guidelines for the symptomatic treatment of MCI. Due to its beneficial effects on cerebrovascular blood flow, it is reasonable to expect that EGb 761® may benefit MCI patients with underlying CVD. Conclusion: As an expert group, we suggest it is clinically appropriate to incorporate EGb 761® as part of the multidomain intervention for MCI. © 2020 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.

基金：
During the last three years: Nagaendran Kandiah has received grant funding and honorarium payments from Novartis Pharmaceuticals, Eisai Pharmaceuticals, Lundbeck, Schwabe Pharma. Chan Yee Fai has received honoraria and CME sponsorship from DCH Auriga, Eisai, Johnson & Johnson, Lundbeck and Novartis as well as involvement in Industry Sponsored Research. Encarnita Ampil has received honoraria from the Lundbeck, Menarini, Medichem, Torrent, Novartis, Kusum Pharma for CME sponsorship, lecture fees and/or module development. D. Darwin A. Dasig. MD has received honoraria, CME sponsorship, lecture fees and/or speaker fees from Hi‐Eisai, Lundbeck, Medichem, and Menarini. Ng Li‐Ling has received honoraria from Novartis, Eisai, MIMS, Schwabe Pharma, and Danone Dumex, and was involved as a consultant, speaker, or in advisory boards for Novartis, Eisai, MIMS, Schwabe Pharma, and Danone Dumex. Paulus Anam Ong has received CME lecture fees from Lundbeck Indonesia, and a grant from Universitas Padjadjaran Bandung Indonesia. Jacqueline Dominguez has received honoraria and CME sponsorship from HI‐Eisai Pharmaceutical Phil., Inc, Menarini Inc Philippines, and Schwabe Pharma; was involved as a consultant, speaker, or in advisory boards for HI‐Eisai Pharmaceutical Phil., Inc, and Menarini Inc Philippines, and EVER Pharma; and received a research grant from the Philippine Institute for Traditional and Alternative Healthcare‐Department of Health. Nguyen Dinh Toan has received honoraria from Eisai pharmaceutical company. Panita Limpawattana has received CME sponsorship from A. Menarini (Thailand) Limited. Chuthamanee Suthisisang has received CME sponsorship from A. Menarini (Thailand) Limited. Vorapun Senanarong has received lecture fees from Eisai Thailand, Lundbeck Thailand; was involved as a consultant, speaker, or in advisory boards with Menarini Thailand; and has received a research grant from the Faculty of Medicine in Siriraj Hospital, Thailand Research Fund, and SCB Corporate Social Responsibility (CSR) project.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类 | 2 区 医学
小类 | 2 区 神经科学 2 区 药学
最新[2023]版：
大类 | 1 区 医学
小类 | 2 区 神经科学 2 区 药学
JCR分区：
出版当年[2019]版：
Q1 PHARMACOLOGY & PHARMACY Q2 NEUROSCIENCES
最新[2023]版：
Q1 PHARMACOLOGY & PHARMACY Q1 NEUROSCIENCES

影响因子： 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者：
第一作者机构： [*1]National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
通讯作者：
通讯机构： [*1]National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
推荐引用方式(GB/T 7714)：
Kandiah N,Chan Y.F,Chen C,et al.Strategies for the use of Ginkgo biloba extract, EGb 761®, in the treatment and management of mild cognitive impairment in Asia: Expert consensus (Open Access)[J].CNS NEUROSCIENCE & THERAPEUTICS.2021,27(2):149-162.doi:10.1111/cns.13536.
APA：
Kandiah, N,Chan, Y.F,Chen, C,Dasig, D,Dominguez, J...&Ihl, R.(2021).Strategies for the use of Ginkgo biloba extract, EGb 761®, in the treatment and management of mild cognitive impairment in Asia: Expert consensus (Open Access).CNS NEUROSCIENCE & THERAPEUTICS,27,(2)
MLA：
Kandiah, N,et al."Strategies for the use of Ginkgo biloba extract, EGb 761®, in the treatment and management of mild cognitive impairment in Asia: Expert consensus (Open Access)".CNS NEUROSCIENCE & THERAPEUTICS 27..2(2021):149-162

相关文献

[1]Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761((R)) [2]轻度认知功能损害的BOLD-fMRI研究进展 [3]银杏叶提取物注射液临床应用中国专家共识（2019） [4]Non-invasive brain stimulation for improving cognitive function in people with dementia and mild cognitive impairment [5]Validation of a Computerized Cognitive Training Tool to Assess Cognitive Impairment and Enable Differentiation Between Mild Cognitive Impairment and Dementia [6]Depression, Anxiety, and Apathy in Mild Cognitive Impairment: Current Perspectives. [7]Different cognitive profiles between mild cognitive impairment due to cerebral small vessel disease and mild cognitive impairment of Alzheimer's disease origin [8]轻度认知障碍与无痴呆型血管性认知障碍患者的神经心理学特征 [9]Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID) [10]Serum Homocysteine, Vitamin B12, Folate, and Their Association with Mild Cognitive Impairment and Subtypes of Dementia

资源点击量：16409 今日访问量：0 总访问量：869 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持：重庆聚合科技有限公司 地址：北京市西城区长椿街45号宣武医院